<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267225</url>
  </required_header>
  <id_info>
    <org_study_id>D-VZR_2015_3</org_study_id>
    <nct_id>NCT03267225</nct_id>
  </id_info>
  <brief_title>Genetic Determinants of Clindamycin/Rifampin Interaction</brief_title>
  <acronym>CLINDA-RIFAM</acronym>
  <official_title>Study on the Genetic Determinants of Clindamycin/Rifampin Interaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Valerie ZELLER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Diaconesses Croix Saint-Simon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective- To study the influence of the polymorphisms of nuclear receptor proteins&#xD;
      pregnane X receptor (PXR), Liver X receptor alpha (LXRα), and Cytochrome P450 (CYP450) on the&#xD;
      clindamycin clearance during clindamycin/rifampin combination therapy.&#xD;
&#xD;
      Secondary objectives To study the influence of these polymorphisms on clindamycin clearance,&#xD;
      before combination therapy with rifampin (clindamycin monotherapy) To study the influence of&#xD;
      these polymorphisms on CYP450 activity before combination therapy with rifampin (clindamycin&#xD;
      monotherapy) To study the influence of these polymorphisms on the increase of CYP450 activity&#xD;
      after clindamycin/rifampin combination therapy To study the difference between the expected&#xD;
      and observed clindamycin serum concentrations after dosage adjustment, in patients with&#xD;
      clindamycin dosage adjustment after combination therapy with rifampin&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be informed on the study during their hospitalisation in the unit for&#xD;
      the treatment of bone and joint infection by the medical doctor. If they agree to participate&#xD;
      in the study, the following samples will be performed :&#xD;
&#xD;
        -  After at least 24 hours of clindamycin therapy and before combination therapy with&#xD;
           rifampin:&#xD;
&#xD;
             -  1 urine sample (5 mL) for CYP 450 activity phenotyping&#xD;
&#xD;
             -  1 blood sample (5 mL on ethylenediaminetetraacetic acid (EDTA) tubes) for measuring&#xD;
                clindamycin serum concentration and genotyping&#xD;
&#xD;
        -  After ten days of clindamycin-rifampin combination therapy:&#xD;
&#xD;
             -  1 urine sample (5 mL) for CYP 450 activity phenotyping&#xD;
&#xD;
             -  1 blood sample (5 mL on EDTA tubes) for measuring clindamycin serum concentration&#xD;
                and genotyping&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic polymorphism of PXR, LXRalpha, CYP450 on clindamycin clearance with clindamycin/rifampin combination therapy</measure>
    <time_frame>10 days after onset of clindamycin/rifampin combination therapy</time_frame>
    <description>Impact of PXR, LXRα, CYP 450 3A4/A5 polymorphism on clindamycin clearance after combination clindamycin-rifampin therapy will be analyzed by studying the association of these polymorphisms and clindamycin serum concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphism of PXR, LXRalpha, CYP450 on clindamycin clearance before combination therapy with rifampin (clindamycin monotherapy)</measure>
    <time_frame>One to four days after onset of clindamycin therapy and before starting rifampin therapy</time_frame>
    <description>Impact of PXR, LXRα, CYP 450 3A4/A5 polymorphism on clindamycin clearance before rifampin therapy will be analyzed by studying the association of these polymorphisms and clindamycin serum concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphism of PXR, LXRalpha, CYP450 on the increase of CYP 3A4 activity before combination therapy with rifampin</measure>
    <time_frame>One to four days after onset of clindamycin therapy and before starting rifampin therapy</time_frame>
    <description>Impact of PXR, LXRα, CYP 450 3A4/A5 polymorphism on CYP 450 3A activity before combination therapy with rifampin will be analyzed by studying the association of these polymorphisms and clindamycin serum concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphism of PXR, LXRalpha, CYP450 on the increase of CYP 3A4 activity after clindamycin/rifampin combination therapy</measure>
    <time_frame>10 days after onset of clindamycin/rifampin combination therapy</time_frame>
    <description>Impact of PXR, LXRα, CYP 450 3A4/A5 polymorphism on CYP 450 3A activity after combination with rifampin therapy will be analyzed by studying the association of these polymorphisms and clindamycin serum concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between expected and observed clindamycine serum concentration after dosage adjustment, in patients after combination therapy with clindamycin and rifampin,.</measure>
    <time_frame>10 days after onset of clindamycin/rifampin combination therapy</time_frame>
    <description>The gap between the predicted and observed clindamycin serum concentrations will be quantified by MPE (Mean Prediction Errors) and RMSE (Root Mean Square Prediction Errors). Dosage adjustment will be considered predictive of the concentration if MPE and RMSE are &lt; 20 %.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>VA Drug Interaction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patient treated for a bone or joint infection with a clindamycin/rifampin combination&#xD;
        therapy, for at least 10 days&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  bone or joint infection&#xD;
&#xD;
          -  aged ≥ 18 years old&#xD;
&#xD;
          -  treatment with clindamycin/rifampin combination therapy &gt; 10 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prescription of another treatment with potential action on CYP450&#xD;
&#xD;
          -  pregnant or breast feeding patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Zeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GH Diaconesses Croix Saint Simon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie ZELLER, MD</last_name>
    <phone>0144641780</phone>
    <email>vzeller@hopital-dcss.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence SALOMON, MD, PhD</last_name>
    <phone>0148036431</phone>
    <email>lsalomon@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Diaconesses Croix Saint-Simon</investigator_affiliation>
    <investigator_full_name>Dr Valerie ZELLER</investigator_full_name>
    <investigator_title>MD, principal investigator</investigator_title>
  </responsible_party>
  <keyword>drug interaction</keyword>
  <keyword>genetic polymorphism</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

